MarketCapExport financials
Concert Pharmaceuticals (CNCE)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Concert Pharmaceuticals Income Statement 2021-2011 | CNCE
Brief overview of profit and loss at Concert Pharmaceuticals
The figures are compared over a five-year interval. Concert Pharmaceuticals reported revenue of 21 thousand dollars in 2016 and 32.6 million dollars by 2021. The five-year change reached +155033.3%, while CAGR stood at 334.7%. Revenue growth reflects a pronounced phase of business expansion.
EBITDA changed from −50.3 million dollars to −76 million dollars (−51.2%). EBITDA underperformed the top-line trend. EBITDA margin was −239400% at the start and −233.4% at the end. The increased EBITDA share is a positive sign.
The net financial result changed from −$50.7 million to −$80.1 million. The period ended with a larger loss than it began with.
Market value was 197 million dollars at the start and 104 million dollars at the end. Market expectations deteriorated over the period.
Overall conclusion
The indicators point to a weaker financial profile. The positive side is supported by sales growth and positive operating leverage. The overall view is constrained by a low EBITDA margin, a weaker market valuation and declining net profitability. Further direction will depend on top-line growth, operating profitability, and net income.
Annual Income Statement Concert Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
104 M | 327 M | 254 M | 331 M | 455 M | 197 M | 323 M | 209 M | - | - | - |
Shares |
34.4 M | 31.2 M | 23.7 M | 23.4 M | 22.6 M | 22.2 M | 21.2 M | 15.8 M | 1.29 M | 1.29 M | - |
Historical Prices |
3.03 | 10.5 | 10.7 | 14.2 | 20.1 | 8.85 | 15.3 | 13.2 | - | - | - |
Net Income |
-80.1 M | -74.8 M | -20.5 M | -20.8 M | -6.07 M | -50.7 M | 24.2 M | -31.7 M | -6.06 M | -20.4 M | -11.3 M |
Revenue |
32.6 M | 7.9 M | 13 K | 10.5 M | 12 K | 21 K | 66.7 M | 8.58 M | 25.4 M | 12.8 M | 19.5 M |
Gross Profit |
- | 7.9 K | - | - | - | - | 66.7 M | 8.58 M | 25.4 M | 12.8 M | - |
Operating Income |
-77.5 M | -72.6 M | -21 M | -20.1 M | -12.7 M | -51.2 M | 24.8 M | -30.6 M | -4.41 M | -18.6 M | - |
Interest Expense |
- | - | - | - | - | - | -309 K | -1.15 M | -1.67 M | -1.86 M | - |
EBITDA |
-76 M | -71 M | -19.3 M | -18.8 M | -11.7 M | -50.3 M | 25.6 M | -29.5 M | -3.06 M | -17.2 M | -9.73 M |
Operating Expenses |
110 M | 80.5 M | 21 M | 20.1 M | 12.7 M | 51.3 M | 41.9 M | 39.2 M | 29.8 M | 31.5 M | 30.8 M |
General and Administrative Expenses |
22.5 M | 18.9 M | 20.3 M | 22.9 M | 21 M | 14.4 M | 13.1 M | 11.7 M | 8.03 M | 7.27 M | 7.38 M |
All numbers in USD currency
Quarterly Income Statement Concert Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
- | 49.7 M | 41 M | 36.7 M | 34.7 M | 34.1 M | 34 M | 33.9 M | 31.9 M | 31.5 M | 31.5 M | 29.1 M | 23.9 M | 23.8 M | 23.8 M | 23.5 M | 23.4 M | 23.4 M | 23.4 M | 23.2 M | 23.1 M | 22.7 M | 22.6 M | 22.4 M | 22.3 M | 22.2 M | 22.2 M | 22.2 M | 22.2 M | 21.9 M | 21.8 M | 18.7 M | 18.2 M | 18.1 M | 17.9 M | 9.19 M | 1.3 M | 1.29 M | 1.29 M | 1.29 M | - | - | - | - | - | - | - | - |
Net Income |
- | -28.9 M | -23.5 M | -37.7 M | - | -26.7 M | 5.42 M | -22.7 M | -22.4 M | -18.9 M | -13 M | -20.5 M | -20.5 M | -17.2 M | -18.7 M | -21.8 M | -20.8 M | -17.4 M | -13.3 M | -4.46 M | -6.07 M | 128 M | -26.4 M | -13.3 M | -12 M | -11.4 M | -13.4 M | -13.9 M | 684 K | -8.55 M | 41 M | -9 M | -8.93 M | -7.83 M | -7.99 M | -6.95 M | -5.92 M | -7.13 M | 8.76 M | -1.78 M | - | - | - | - | - | - | - | - |
Revenue |
- | 8 K | 21 K | - | - | 543 K | 32 M | 5 K | 7 K | 1.5 M | 6.39 M | 7 K | 13 K | 10 K | 49 K | 1 M | 13 K | 11 K | 2 K | 10.5 M | 12 K | 144 M | 15 K | 20 K | 21 K | 26 K | 71 K | 56 K | 10.3 M | 1.71 M | 53.4 M | 1.31 M | 1.31 M | 4.42 M | 1.24 M | 1.61 M | 1.41 M | 681 K | 17.4 M | 5.87 M | - | - | - | - | - | - | - | - |
Operating Income |
- | -29.6 M | -25.7 M | -36 M | - | -26.8 M | 6.22 M | -24 M | -21.5 M | -19.4 M | -13.1 M | -18.7 M | -21 M | -18.2 M | -19.4 M | -20.4 M | -20.1 M | -17.3 M | -14.4 M | -3.81 M | -12.7 M | 132 M | -13 M | -13.5 M | -12.2 M | -11.5 M | -13.6 M | -14 M | 663 K | -8.69 M | 41.7 M | -8.87 M | -8.74 M | -7.61 M | -7.73 M | -6.52 M | -5.58 M | -7.12 M | 9.42 M | -1.13 M | - | - | - | - | - | - | - | - |
Interest Expense |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -609 K | -205 K | - | - | - | - | - | - | -58 K | -103 K | -148 K | - | -239 K | -280 K | -435 K | - | -14 K | -653 K | -660 K | - | - | - | - | - | - | - | - |
EBITDA |
- | -28.7 M | -25 M | -35.7 M | - | -25.6 M | 7 M | -23.6 M | -21.5 M | -18.2 M | -12.3 M | -18.2 M | -21 M | -17 M | -18.6 M | -20 M | -20.1 M | -16.5 M | -13.9 M | -3.55 M | -12.7 M | 133 M | -12.5 M | -13.2 M | -12.2 M | -10.8 M | -13.1 M | -13.8 M | 663 K | -8.12 M | 42.1 M | -8.69 M | -8.74 M | -6.63 M | -7.08 M | -6.19 M | -5.58 M | -6.11 M | 10.1 M | -792 K | - | - | - | - | - | - | - | - |
Operating Expenses |
- | 29.6 M | 25.7 M | 36 M | - | 27.3 M | 25.8 M | 24 M | 21.5 M | 20.9 M | 19.5 M | 18.7 M | 21 M | 18.3 M | 19.5 M | 21.4 M | 20.1 M | 17.4 M | 14.4 M | 14.3 M | 12.7 M | 12 M | 13 M | 13.5 M | 12.2 M | 11.5 M | 13.6 M | 14 M | 9.64 M | 10.4 M | 11.7 M | 10.2 M | 10.1 M | 12 M | 8.96 M | 8.13 M | 6.99 M | 7.8 M | 8.03 M | 7 M | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
- | 5.25 M | 4.85 M | 5.54 M | - | 5.46 M | 5.61 M | 5.48 M | - | 4.51 M | 4.73 M | 4.67 M | - | 4.74 M | 4.98 M | 5.61 M | - | 6.32 M | 5.51 M | 5.63 M | - | 4.88 M | 5.71 M | 5.25 M | - | 3.44 M | 3.83 M | 3.58 M | - | 3.27 M | 3.3 M | 3.23 M | - | 3.46 M | 2.72 M | 2.54 M | - | 2.13 M | 2.27 M | 1.96 M | - | - | - | - | - | - | - | - |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Concert Pharmaceuticals (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Фармсинтез
LIFE
|
- | - | - |  Russia |
 |
Aclaris Therapeutics
ACRS
|
$ 5.64 | 5.92 % | $ 691 M |  USA |
 |
Akebia Therapeutics
AKBA
|
$ 0.99 | 4.33 % | $ 255 M | USA |
 |
Alector
ALEC
|
$ 2.19 | 2.1 % | $ 226 M | USA |
 |
Aligos Therapeutics
ALGS
|
$ 5.08 | 0.96 % | $ 50.2 M | USA |
 |
Alkermes plc
ALKS
|
$ 45.83 | 0.22 % | $ 7.55 B |  Irlanda |
 |
Allogene Therapeutics
ALLO
|
$ 1.79 | 0.28 % | $ 395 M | USA |
 |
Alnylam Pharmaceuticals
ALNY
|
$ 248.37 | 0.14 % | $ 32.5 B | USA |
 |
Altimmune
ALT
|
$ 3.31 | 1.22 % | $ 292 M | USA |
 |
ALX Oncology Holdings
ALXO
|
$ 1.93 | 0.52 % | $ 104 M | USA |
 |
Amgen
AMGN
|
$ 380.17 | 0.75 % | $ 205 B | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
$ 23.96 | 0.74 % | $ 1.12 B | USA |
 |
Amarin Corporation plc
AMRN
|
$ 14.02 | 1.59 % | $ 5.82 B | Irlanda |
 |
Amneal Pharmaceuticals
AMRX
|
$ 17.23 | 1.29 % | $ 5.4 B | USA |
 |
AbbVie
ABBV
|
$ 261.94 | 1.87 % | $ 463 B | USA |
 |
AnaptysBio
ANAB
|
$ 54.77 | 1.67 % | $ 1.58 B | USA |
 |
Anika Therapeutics
ANIK
|
$ 21.22 | 1.7 % | $ 304 M | USA |
 |
ANI Pharmaceuticals
ANIP
|
$ 70.92 | 1.04 % | $ 1.42 B | USA |
 |
Aprea Therapeutics
APRE
|
$ 0.76 | 2.03 % | $ 4.97 M | USA |
 |
Aptevo Therapeutics
APVO
|
$ 1.87 | 2.75 % | $ 590 K | USA |
 |
AbCellera Biologics
ABCL
|
$ 11.04 | 1.38 % | $ 3.3 B |  Canada |
 |
Aquestive Therapeutics
AQST
|
$ 4.89 | 2.41 % | $ 523 M | USA |
 |
Arcturus Therapeutics Holdings
ARCT
|
$ 15.23 | 3.39 % | $ 417 M |  Israel |
 |
Ardelyx
ARDX
|
$ 3.54 | 0.14 % | $ 853 M | USA |
 |
Armata Pharmaceuticals
ARMP
|
$ 5.3 | 1.84 % | $ 192 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
$ 24.35 | 1.95 % | $ 3.1 B | USA |
 |
Artelo Biosciences
ARTL
|
$ 5.15 | 1.1 % | $ 974 K | USA |
 |
Arvinas
ARVN
|
$ 8.44 | 0.41 % | $ 598 M | USA |
 |
Arrowhead Pharmaceuticals
ARWR
|
$ 80.24 | 0.11 % | $ 10.7 B | USA |
 |
Assembly Biosciences
ASMB
|
$ 28.86 | 0.64 % | $ 324 M | USA |
 |
Actinium Pharmaceuticals
ATNM
|
$ 1.25 | 6.87 % | $ 39 M | USA |
 |
Atara Biotherapeutics
ATRA
|
$ 9.49 | 1.17 % | $ 119 M | USA |
 |
Agenus
AGEN
|
$ 7.12 | 2.59 % | $ 212 M | USA |
 |
Aurinia Pharmaceuticals
AUPH
|
$ 16.3 | 1.26 % | $ 2.19 B | Canada |
 |
Autolus Therapeutics plc
AUTL
|
$ 1.94 | 2.93 % | $ 516 M |  Britain |
 |
Atea Pharmaceuticals
AVIR
|
$ 5.34 | 0.47 % | $ 435 M | USA |
 |
Axon Enterprise
AXON
|
$ 491.2 | 2.47 % | $ 38.4 B | USA |
 |
Axsome Therapeutics
AXSM
|
$ 216.73 | 0.75 % | $ 10.8 B | USA |
 |
Aytu BioScience
AYTU
|
$ 2.0 | 0.5 % | $ 12.6 M | USA |
 |
BridgeBio Pharma
BBIO
|
$ 72.33 | 0.1 % | $ 13.9 B | USA |
 |
BioCryst Pharmaceuticals
BCRX
|
$ 8.2 | 0.92 % | $ 1.72 B | USA |
 |
Bicycle Therapeutics plc
BCYC
|
$ 3.87 | 0.13 % | $ 268 M | Britain |
 |
Black Diamond Therapeutics
BDTX
|
$ 2.03 | 2.52 % | $ 115 M | USA |
 |
Beam Therapeutics
BEAM
|
$ 24.35 | 1.5 % | $ 2.41 B | USA |
 |
Biogen
BIIB
|
$ 217.62 | 0.22 % | $ 31.9 B | USA |
 |
BioLineRx Ltd.
BLRX
|
$ 2.48 | 0.2 % | $ 6.11 B | Israel |
 |
BioMarin Pharmaceutical
BMRN
|
$ 66.22 | 0.82 % | $ 12.7 B | USA |
 |
Bristol-Myers Squibb Company
BMY
|
$ 64.03 | 0.61 % | $ 130 B | USA |
 |
Benitec Biopharma
BNTC
|
$ 12.11 | 0.08 % | $ 498 M | USA |
 |
Burford Capital Limited
BUR
|
$ 4.35 | 1.13 % | $ 953 M | Britain |